Physician profile
Bryan A Strelow
NPI 1598299257
$7,102.45
in general payments reported to CMS, 2019-2025
21 companies · $4,389 in 2025
The $4,389 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $176 · 2021: $362 · 2022: $274 · 2023: $800 · 2024: $883 · 2025: $4,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,184 · Food and Beverage: $2,783 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,183.97 |
| Food and Beverage | $2,783.32 |
| Education | $105.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $3,462.10 | 2024-2025 | Dextenza |
| Regeneron Healthcare Solutions, INC. | $986.63 | 2022-2025 | Eylea Hd, Eylea |
| Johnson & Johnson Surgical Vision, INC. | $624.65 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $483.11 | 2022-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $367.57 | 2022-2025 | Stellaris, Xipere, Visudyne |
| Alimera Sciences, INC. | $245.19 | 2023-2024 | Yutiq, Iluvien |
| Mallinckrodt Hospital Products INC. | $228.35 | 2020-2024 | Acthar |
| Regeneron Pharmaceuticals, INC. | $109.81 | 2022 | |
| Abbvie INC. | $95.70 | 2023-2025 | Durysta |
| Alcon Vision LLC | $85.01 | 2025 | Constellation, Rocklatan |
| Genentech USA, INC. | $84.67 | 2024-2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $69.33 | 2025 | Iluvien, Yutiq |
| New World Medical,INC. | $46.39 | 2021 | |
| Biotissue Holdings INC. | $43.51 | 2021 | |
| Harrow Eye, LLC | $36.95 | 2024 | Iheezo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $27.88 | 2025 | Xdemvy |
| Sandoz INC. | $27.35 | 2024 | Cimerli |
| Glaukos Corporation | $26.37 | 2019-2021 | |
| Astellas Pharma US INC | $21.88 | 2025 | Izervay |
| Biogen, INC. | $16.31 | 2023 | |
| Eyepoint US, INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Strelow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.